{"id":"W4221104500","doi":"10.1158/1538-7445.sabcs21-pd15-01","title":"Abstract PD15-01: Impact of <i>ESR1</i> mutations on endocrine therapy (ET) plus alpelisib benefit in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), <i>PIK3CA</i>-mutated, advanced breast cancer (ABC) who progressed on or after prior cyclin-dependent kinase inhibitor (CDK4/6i) therapy in the BYLieve trial","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Cohort; Internal medicine; Fulvestrant; Oncology; Clinical endpoint; Hazard ratio; Progression-free survival; Clinical trial; Cancer; Estrogen receptor; Confidence interval; Breast cancer; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001306242,0.0005828425,0.001222955,0.0001607811,0.000178568,0.001267404,0.0005556173,0.0005689169,0.004136872],"category_scores_gemma":[0.001037286,0.0002044209,0.001477918,0.0002553541,0.0004929441,0.0005762557,0.0003760431,0.002130208,0.0005588106],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000494063,"about_ca_system_score_gemma":0.0008291451,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004791607,"about_ca_topic_score_gemma":0.001185568,"domain_scores_codex":[0.9996212,0.0001900002,0.00002940618,0.00007228469,0.00003450301,0.00005253545],"domain_scores_gemma":[0.9993582,0.0001446973,0.0001524006,0.00005067379,0.00004156721,0.0002525016],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.8987663,0.004568655,0.01416536,0.001017168,0.002403586,0.00007123942,0.0001060904,0.001372985,0.009389469,0.0005154419,0.005801158,0.06182254],"study_design_scores_gemma":[0.7315964,0.1990997,0.04771166,0.0002319436,0.003428007,0.0003825537,0.0001236575,0.002605633,0.004554813,0.001161715,0.009046586,0.00005741258],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9913871,0.002649823,0.0002098306,0.0005087811,0.0001410524,0.0004171777,0.001964284,0.0000471929,0.002674738],"genre_scores_gemma":[0.9918032,0.001009496,0.0005333714,0.0008620789,0.0001391579,0.0004395594,0.003616267,0.00001603477,0.001580894],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004136872,"threshold_uncertainty_score":0.01383919,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03477374645994236,"score_gpt":0.380465132983951,"score_spread":0.3456913865240087,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}